Fosun Pharma grants share options and RSUs to employees

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. has announced the first grant under its 2025 A Share Option Scheme and 2025 H Share RSU Scheme, following shareholder approval on October 23, 2025. On November 4, 2025, the board approved the A Share Option First Grant of 4,535,100 A Share Options to 195 participants, with an exercise price of RMB27.93 per share. These options represent approximately 0.1698% of the company’s total shares in issue as of November 4, 2025.

Concurrently, the H Share RSU First Grant, also on November 4, 2025, distributed 10,589,500 RSUs to 195 eligible employees, including key executives. The closing price of H Shares on the grant date was HK$22.62 per share. The granted RSUs represent the right to receive restricted H shares, with percentages ranging from 0.0094% to 1.2642% of the total H shares in issue (excluding treasury shares) as of the announcement date.

Following these grants, the total authorized/registered share capital for the company's H-shares and A-shares stands at RMB551,940,500 and RMB2,118,488,825 respectively, totaling RMB2,670,429,325. The number of H Shares remaining available for future grants under the H Share Scheme Mandate Limit is 43,507,650 H Shares.